Sacubitril 24mg/Valsartan 26mg, 49mg/51mg, 97mg/103mg Tablets — Angiotensin Receptor-Neprilysin Inhibitor (ARNI) for Heart Failure
Vymada® (Sacubitril/Valsartan) — First-in-Class ARNI for Heart Failure with Reduced Ejection Fraction
Revolutionary Heart Failure Treatment Combining Neprilysin Inhibition with Angiotensin Receptor Blockade
Vymada® (Sacubitril/Valsartan) is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining Sacubitril — a prodrug of the neprilysin inhibitor sacubitrilat — and Valsartan — an angiotensin II receptor blocker (ARB). Vymada is used to treat symptomatic heart failure with reduced ejection fraction (HFrEF) — reducing cardiovascular death and heart failure hospitalisations in patients who remain symptomatic despite optimal conventional therapy.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Vymada (Sacubitril/Valsartan) to hospitals, cardiology centres, heart failure clinics, and pharmacies across India. Vymada contains the same active ingredients as the originator brand Entresto — manufactured under license by leading pharmaceutical companies — providing equivalent efficacy at accessible pricing for Indian patients.
What is Vymada (Sacubitril/Valsartan)?
Vymada contains two active components in a single tablet:
Sacubitril — a prodrug converted in vivo to sacubitrilat, a neprilysin inhibitor. Neprilysin is an endopeptidase that degrades natriuretic peptides (ANP, BNP, CNP) and other vasoactive peptides. By inhibiting neprilysin, sacubitrilat increases levels of natriuretic peptides — promoting vasodilation, natriuresis, diuresis, and inhibition of maladaptive cardiac remodelling.
Valsartan — an angiotensin II type 1 receptor blocker (ARB) that blocks the renin-angiotensin-aldosterone system (RAAS) — reducing vasoconstriction, sodium retention, and cardiac remodelling driven by angiotensin II.
The combination of neprilysin inhibition and RAAS blockade provides complementary and synergistic cardiovascular benefits — superior to either mechanism alone — making Vymada the most important advance in heart failure pharmacotherapy in two decades.
Full prescribing information is available at the FDA label for Sacubitril/Valsartan.
Clinical Studies and Evidence
PARADIGM-HF Trial (Sacubitril/Valsartan vs Enalapril in HFrEF) Published in the New England Journal of Medicine (2014), the landmark PARADIGM-HF trial — one of the most important heart failure trials ever conducted — demonstrated that Sacubitril/Valsartan significantly reduced the primary composite endpoint of cardiovascular death or first heart failure hospitalisation by 20% compared to Enalapril. The trial was stopped early due to overwhelming efficacy — with cardiovascular death reduced by 20% and heart failure hospitalisation reduced by 21%. This established Sacubitril/Valsartan as superior to ACE inhibitors — the previous standard of care — for HFrEF.
PIONEER-HF Trial (Sacubitril/Valsartan in Acute Decompensated Heart Failure) Published in the New England Journal of Medicine (2019), the PIONEER-HF trial demonstrated that initiating Sacubitril/Valsartan in-hospital during acute decompensated heart failure was safe and significantly reduced NT-proBNP levels compared to Enalapril — supporting early in-hospital initiation.
TRANSITION Trial (Early Initiation Post-Hospitalisation) The TRANSITION trial confirmed the feasibility and safety of initiating Sacubitril/Valsartan either in-hospital or shortly after discharge in stabilised acute heart failure patients — supporting early initiation strategies.
PARAGLIDE-HF Trial (HFpEF and HFmrEF) The PARAGLIDE-HF trial demonstrated benefits of Sacubitril/Valsartan in heart failure with mildly reduced and preserved ejection fraction — expanding the evidence base beyond HFrEF.
Real-World Evidence Multiple real-world registries from Europe, North America, and Asia confirm that Sacubitril/Valsartan reduces cardiovascular mortality and hospitalisation in routine clinical practice — consistent with PARADIGM-HF trial results.
Available Strengths
Vymada is available in the following strengths:
| Tablet | Sacubitril | Valsartan | Equivalent Valsartan dose |
|---|---|---|---|
| Vymada 50mg | 24mg | 26mg | 40mg |
| Vymada 100mg | 49mg | 51mg | 80mg |
| Vymada 200mg | 97mg | 103mg | 160mg |
Treatment is typically started at 50mg twice daily and uptitrated every 2-4 weeks to the target dose of 200mg twice daily as tolerated.
Indications — What Vymada is Used For
Note: Vymada must not be used concomitantly with ACE inhibitors. A washout period of at least 36 hours is required when switching from an ACE inhibitor to Vymada to avoid the risk of angioedema.
For detailed indication information refer to MedlinePlus Sacubitril/Valsartan.
Key Benefits of Vymada
Superior to ACE Inhibitors — The Previous Gold Standard The PARADIGM-HF trial demonstrated Sacubitril/Valsartan is superior to Enalapril — the previous gold standard for HFrEF — reducing cardiovascular death by 20% and heart failure hospitalisation by 21%. This established it as the new standard of care.
Reduces Cardiovascular Mortality A 20% reduction in cardiovascular death represents a clinically profound benefit — for every 32 patients treated for 27 months one cardiovascular death is prevented compared to Enalapril.
Reduces Hospitalisations A 21% reduction in heart failure hospitalisations reduces the enormous clinical and economic burden of recurrent heart failure admissions — improving patient quality of life and reducing healthcare costs.
Improves Symptoms and Quality of Life PARADIGM-HF demonstrated significant improvements in KCCQ (Kansas City Cardiomyopathy Questionnaire) scores — reflecting meaningful patient-reported symptom improvement and quality of life benefit.
Reverses Cardiac Remodelling Sacubitril/Valsartan promotes reverse cardiac remodelling — improving LVEF and reducing left ventricular volumes over time — addressing the underlying cardiac structural abnormality in HFrEF.
Endorsed by All Major Guidelines Vymada/Sacubitril/Valsartan is a Class I, Level A recommendation in ESC, ACC/AHA, and Indian heart failure guidelines — the highest level of evidence-based recommendation.
How Vymada Works
Heart failure with reduced ejection fraction (HFrEF) is characterised by:
Vymada addresses these mechanisms through two complementary pathways:
Sacubitrilat (Neprilysin Inhibitor):
Valsartan (ARB):
Combined ARNI Effect: The combination of neprilysin inhibition (increasing beneficial natriuretic peptides) and RAAS blockade (reducing harmful neurohormonal activation) provides synergistic cardiovascular protection superior to either mechanism alone.
For a detailed mechanism overview refer to the European Society of Cardiology Heart Failure Guidelines.
Heart Failure Treatment Algorithm — Where Vymada Fits
Current guidelines recommend the following foundational therapy for HFrEF:
| Medicine Class | Role | Examples |
|---|---|---|
| ARNI (first choice) | Replace ACE inhibitor/ARB | Vymada (Sacubitril/Valsartan) |
| Beta-blocker | Reduce mortality | Carvedilol, Bisoprolol, Metoprolol |
| MRA | Reduce mortality | Spironolactone, Eplerenone |
| SGLT2 inhibitor | Reduce HF hospitalisation | Dapagliflozin, Empagliflozin |
| Diuretic | Symptom relief | Furosemide, Bumetanide |
Vymada replaces ACE inhibitor or ARB in the foundational quadruple therapy for HFrEF — the combination of ARNI + Beta-blocker + MRA + SGLT2 inhibitor now represents the optimal medical therapy.
Dosage and Administration
ACE Inhibitor/ARB Naive Patients or on Low-Dose ACE/ARB:
Patients on Moderate-High Dose ACE Inhibitor/ARB:
Target Dose:
Switching from ACE Inhibitor:
Administration:
Full dosing guidelines available at Drugs.com Sacubitril/Valsartan Dosage.
Who Should Use Vymada
Vymada is prescribed for:
Vymada is prescribed by cardiologists, heart failure specialists, and general physicians. A.K. Pharma supplies Vymada to hospitals, cardiology centres, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include hypotension, hyperkalaemia, renal impairment, dizziness, cough (less than ACE inhibitors), and fatigue.
Serious side effects include:
Full side effect information available at FDA Sacubitril/Valsartan Safety Information.
Precautions
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Vymada under manufacturer-recommended conditions ensuring product integrity for every supply.
Manufacturer Information
Vymada (Sacubitril/Valsartan) contains the same active ingredients as Entresto — developed by Novartis. Sacubitril/Valsartan received FDA approval in July 2015 for HFrEF — one of the most significant cardiology approvals in two decades. A.K. Pharma supplies only genuine Vymada sourced from authorized distributors.
Related Heart Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Vymada used for? Vymada (Sacubitril/Valsartan) is used to treat heart failure with reduced ejection fraction (HFrEF) — reducing cardiovascular death and heart failure hospitalisations in symptomatic patients. More information available at MedlinePlus.
Q. What is the generic name of Vymada? The generic name of Vymada is Sacubitril/Valsartan. It belongs to the angiotensin receptor-neprilysin inhibitor (ARNI) class of heart failure medicines.
Q. Is Vymada the same as Entresto? Vymada contains the same active ingredients as Entresto (Sacubitril/Valsartan) — providing equivalent pharmacological activity. Both deliver the same doses of Sacubitril and Valsartan in each tablet strength.
Q. Why must ACE inhibitors be stopped before starting Vymada? Concurrent use of Vymada and ACE inhibitors significantly increases the risk of angioedema — a potentially life-threatening swelling of the face, lips, tongue, and airway. A mandatory washout of at least 36 hours after stopping ACE inhibitor is required before starting Vymada.
Q. Is Vymada available in India? Vymada can be supplied to hospitals, cardiology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the price of Vymada in India? Vymada price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Vymada from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Vymada in bulk? Yes. A.K. Pharma supplies Vymada in bulk to hospitals, cardiology centres, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Why Order Vymada from A.K. Pharma?
Contact A.K. Pharma for Vymada Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
